Soligenix Inc. Advances Clinical Programs with Key Trial Results Expected by 2026
Soligenix Inc. is making significant progress in its clinical programs, with critical trial results for treatments of rare diseases like cutaneous T-cell lymphoma and Behçet’s disease expected in the coming years, highlighting the company's role in addressing unmet medical needs.
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced its financial results for the first quarter of 2025, alongside updates on its clinical programs. The company is focused on developing treatments for rare diseases with significant unmet medical needs, with several key milestones anticipated in the near future.
Christopher J. Schaber, PhD, CEO and president of Soligenix, emphasized the company's strategic focus on advancing its clinical programs. Notably, top-line results from a phase 3 confirmatory study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL) are expected in 2026. Additionally, phase 2 studies of SGX945 in Behçet’s disease and SGX302 in mild-to-moderate psoriasis are set to report results in the second half of 2025.
These developments are crucial for patients suffering from rare diseases, offering potential new treatment options where few exist. The progress of Soligenix's clinical programs underscores the importance of continued investment and innovation in the biopharmaceutical sector to address complex medical challenges.